Efficacy and safety of Huachansu combined with chemotherapy in advanced gastric cancer: A meta-analysis

Medical Hypotheses

Volumn 81, Issue 2, 2013, Pages 243-250

  Xie, Xuefeng ^a   Huang, Xiaohui ^a   Li, Jun ^a   Lv, Xiongwen ^a   Huang, Jihan ^b   Tang, Songtao ^a   Sun, Yehuan ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ALKALOID; CAPECITABINE; CHINESE DRUG; CISPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM; HUACHANSU; HYDROXYCAMPTOTHECINE; MITOMYCIN; OXALIPLATIN; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; META ANALYSIS; NEUROTOXICITY; OUTCOME ASSESSMENT; QUALITY OF LIFE; STOMACH CANCER; TREATMENT DURATION; TREATMENT RESPONSE;

AMPHIBIAN VENOMS; ANTINEOPLASTIC AGENTS; HUMANS; STOMACH NEOPLASMS;

ANURA; BUFO GARGARIZANS; BUFO MELANOSTICTUS;

EID: 84880045918     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.04.038     Document Type: Article

References (37)

1. American Cancer Society. Global cancer facts & figures. 2nd ed.; 2011 [accessed 03.01.12]. http://www.cancer.org/Research/CancerFactsFigures/Global-CancerFactsFigures/index.
2. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
3. Patricia B., Fernando M.G., Pelayo C., et al. Risk factors for gastric cancer in Latin America: a meta-analysis. Cancer Causes Control 2013, 24:217-231.
4. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010, 303:1729-1737.
5. Xu W., Towers A.D., Li P., Collet J.P. Traditional Chinese medicine in cancer care: perspectives and experiences of patients and professionals in China. Eur J Cancer Care (Engl) 2006, 15:397-403.
6. Konkimalla V.B., Efferth T. Evidence-based Chinese medicine for cancer therapy. J Ethnopharmacol 2008, 116:207-210.
7. Doreen O., Jawaid Y. Natural health products and cancer chemotherapy and radiation therapy. Oncol Rev 2008, 1:233-242.
8. Su Y.H., Nu X. Evaluation of pharmacodynamic effect of pharmaceutical agents of Chan Su. J Beijing Univ TCM 2001, 24:51-54.
9. Lu C.X., Nan K.J., Lei Y. Agents from amphibians with anticancer properties. Anticancer Drugs 2008, 19:931-939.
10. Qi F.H., Li A.Y., Inagaki Yoshinori, et al. Chinese herbal medicines as adjuvant treatment during chemo-or radio-therapy for cancer. BioScience Trends 2010, 4:297-307.
11. Zhu X.Y., Liu L.M. Research progress on the antitumor mechanism of Cinobutacini injection and its active ingredient. Tumor J World 2006, 5:272-275.
12. Meng Z.Q., Yang P.Y., Shen Y.H., Bei W.Y., et al. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer 2009, 115:5309-5318.
13. Newman R.A., Yang P., Pawlus A.D., Block K.I. Cardiac glycosides as novel cancer therapeutic agents. Mol Interv 2008, 8:36-49.
14. Wang J., Jin Y., Xu Z., Zheng Z., Wan S. Involvement of caspase-3 activity and survivin down regulation in cinobufocini-induced apoptosis in A 549 cells. Exp Biol Med 2009, 234:566-572.
15. Qi F.H., Li A.Y. Yoshinori Inagaki, et al. Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol 2011, 11:342-349.
16. Zhong J.S., Chen G.P., Guo J.W. Clinical observation on HuaChanSu in treating hepatocellular carcinoma after transarterial chemoembolization (TACE). Cancer Prev Treat 2002, 29:67-69.
17. Huang P.M., Chen W.W., Xie X.F., et al. Investigation about the rationality of drug use in Feixi township hospitals under the background of new medical reform. Anhui Med Pharm J 2012, 16:256-258.
18. Higgins J.P., Thompson S.G., Deeks J.J., et al. Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
19. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
20. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
21. Zhang C.W., Wang Q.H. Efficiency and safety of Huachansu combined with chemotherapy in advanced gastric cancer: 35 cases study. J Anhui TCM College 2001, 20:18-19.
22. Zhang R.G., Cheng Z.H., Shen B., Zhou D.M., Zhuang G.X. Clinical observation of the Huachansu combined with chemotherapy in advanced gastric cancer. Chin Clin Oncol 2004, 3:269-270.
23. Zhang Y., Zhu M., Cao Y., Zhang P., Yao L.G., Huang H.X. Efficiency of Huachansu combined with chemotherapy in treatment of advanced gastric cancer. Henan J Oncol 2005, 5:359-360.
24. Zhang Z.Q., Wang Y., Rong D.Q. The short-term therapeutic effect of cinobufacini combined with hydroxycamptothecin for advanced stomach cancer. Prac J Med Pharm 2006, 23:794-795.
25. Zheng Y.L., Ma B.H., Yang F. Clinical observation of the Huachansu combined with chemotherapy in treatment of advanced gastric cancer. Qingdao Med J 2007, 39:260-261.
26. Ren L.X., Wang Y.H., Ha M.W. Clinical study of the Huachansu combined with chemotherapy in treatment of advanced gastric cancer. China J Chin Mater Med 2008, 33:1474-1475.
27. Chen H.M. The therapeutic effect of cinobufacini combined with TPF regimen for advanced stomach cancer. J Emergency Tradit Chin Med 2009, 18:35-36.
28. Wang Y.H. Clinical observation of Huachansu combined with chemotherapy in treatment of advanced gastric cancer: 36 cases study. Jiangxi J Tradit Chin Med 2009, 4:31-32.
29. Wang W.M., Li C.F., Yao R.J. Clinical observation of Huachansu combined with chemotherapy in treatment of advanced gastric cancer. Clin J Tradit Chin Med 2010, 22:314-315.
30. Guo C.J., Yu T.H., Zhang H.P., Xing J.H. The observation of clinical therapeutic effect of Cinobufacini combined with Docetaxel on advanced stomach cancer. China Med Herald 2011, 8:54-55.
31. Zhu W.K., Li Y., Hou F.G., Chen M., Zhou Y.Y. Efficacy of Cinobufacini combined with CapeOX regimen in treatment of advanced gastric cancer. China Med Herald 2012, 9:35-36.
32. Chen G.F., Jin D.X., Li M.J. The therapeutic effect of Huchansu combined with Capecitabine in treatment of advanced gastric cancer. Zhejiang J Tradit Chin Med 2012, 47:462-463.
33. Zou H.P., Guo X.Z., Zhu Y.F. Clinical research on Huchansu with EOF Regimen in patients with advanced gastric cancer. Chin J Clin Med 2012, 19:140-141.
34. Wang Z.F., Wang P. The therapeutic effect of Huachansu combined with chemotherapy in treatment of advanced gastric cancer. Chin J Primary Med Pharm 2012, 19:1991-1992.
35. Wang X.W., Qin Z.F. Cinobufagin injection combined chemotherapeutics in advanced gastric carcinoma. Mod J Integr Tradit Chin Western Med 2012, 21:235-238.
36. The GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Cancer 2013;7:1565-77.
37. Wagner A.D., Unverzagt S., Grothe W., et al. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006, 24:2903-2909.